ARTV Stock Analysis: Buy, Sell, or Hold?
ARTV - Artiva Biotherapeutics, Inc. Common Stock
$10.81
0.04 (0.42%)
▲
5d:
+2.61%
30d:
+14.46%
90d:
-4.3%
BUY
MODERATE Confidence
Analysis Updated: Aug 3, 2026 12:00 AM ET
Earnings: Aug 05, 2026
TODAY
Get Alerted When ARTV Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ARTV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: ARTV shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: ARTV is currently trading at $10.80, which is considered extended relative to its 30-day fair value range of $9.33 to $10.29.
Technical Outlook: Technically, ARTV is in a uptrend. Immediate support is located at $9.04, while resistance sits at $11.30.
Market Sentiment: ARTV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.80 (+232.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ARTV is in a uptrend. Immediate support is located at $9.04, while resistance sits at $11.30.
Market Sentiment: ARTV has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $35.80 (+232.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$9.33 -
$10.29
Company Quality Score
52/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
66.7%
All Signals
- BEARISH: Price extended above range (+5.0% above its trading range)
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 232.7% below Wall St target ($35.80)
Trading Range Analysis
30-Day Trading Range
$9.33 -
$10.29
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$1.34
(12.4%)
Support & Resistance Levels
Support Level
$9.04
Resistance Level
$11.30
Current Trend
Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.82
Wall Street Target
$35.80
(+232.7%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: August 04, 2026 11:13 AM ET
Data refreshes hourly during market hours. Next update: 12:13 PM
Data refreshes hourly during market hours. Next update: 12:13 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ARTV showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 55 HOLD |
|
RNA
Atrium Therapeutics, Inc… |
STRONG BUY
15 analysts |
$25 | 55 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$123 | 54 HOLD |
|
VRDN
Viridian Therapeutics Inc |
STRONG BUY
16 analysts |
$36 | 61 BUY |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 60 BUY |
